Showing results (241-250 of 304) with videos related to

Sort By:
Pageof 31
Translational Oncology|June 27, 2025
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomicsLorenzo Foffano, Alessandra Franzoni, Elisabetta Molteni, et al.
Therapeutic Advances in Medical Oncology|March 20, 2023
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Luisa Carbognin, Isabella Sperduti, et al.
Cancer Treatment Reviews|August 28, 2023
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spreadCarmen Criscitiello, Chiara Corti, Michelino De Laurentiis, et al.
Journal of the National Cancer Institute|February 5, 2025
Prognostic implications of risk definitions from the monarchE and NATALEE trialsLuca Arecco, Eva Blondeaux, Marco Bruzzone, et al.
Science Advances|November 13, 2024
USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activityAnna Nespolo, Linda Stefenatti, Ilenia Pellarin, et al.
Breast (Edinburgh, Scotland)|March 5, 2013
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trialDiana Crivellari, Kathryn P Gray, Silvia Dellapasqua, et al.
Breast (Edinburgh, Scotland)|December 30, 2017
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Mario Giuliano, Francesco Schettini, et al.
NPJ Breast Cancer|June 29, 2021
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancerFabio Puglisi, Lorenzo Gerratana, Matteo Lambertini, et al.
Cancer Letters|November 22, 2024
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profilingLorenzo Gerratana, Andrew A Davis, Lorenzo Foffano, et al.
Breast (Edinburgh, Scotland)|June 27, 2026
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trialChiara Molinelli, Virginia Delucchi, Eva Blondeaux, et al.
Pageof 31